Benchmark Maintains Speculative Buy on ImmunoPrecise Antibodies, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman maintains a Speculative Buy rating on ImmunoPrecise Antibodies (NASDAQ:IPA) but lowers the price target from $5 to $3.
August 14, 2024 | 5:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Benchmark analyst Robert Wasserman maintains a Speculative Buy rating on ImmunoPrecise Antibodies but lowers the price target from $5 to $3.
The lowered price target from $5 to $3 suggests a less optimistic outlook for ImmunoPrecise Antibodies, which could negatively impact short-term stock price despite the maintained Speculative Buy rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100